80%Confidence
0Views
FDASource
2026-04-07Date
Summary
Apotex's Class II recall for Brimonidine/Timolol ophthalmic solution over sterility issues highlights quality control lapses in a sterile product category. This may lead to temporary market withdrawal and increased scrutiny of Apotex's manufacturing practices.
Actionable: Monitor Apotex's recall execution and any potential market share shifts in ophthalmic solutions.
AI Confidence: 80%
Data Points
firmApotex Corp.
classificationClass II
statusOngoing
distributionU.S. Nationwide
productBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 3
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now